Treprostinil Palmitil ( DrugBank: Treprostinil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,181 /  Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05147805 (ClinicalTrials.gov)	March 31, 2022	24/11/2021	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension	A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Treprostinil Palmitil;Drug: Placebo	Insmed Incorporated	NULL	Recruiting	18 Years	75 Years	All	99	Phase 2	United States
2	NCT04791514 (ClinicalTrials.gov)	May 31, 2021	8/3/2021	Open Label Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)	An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Treprostinil Palmitil	Insmed Incorporated	NULL	Recruiting	18 Years	N/A	All	10	Phase 2	United States